Ignite Creation Date:
2025-12-24 @ 9:31 PM
Ignite Modification Date:
2026-01-05 @ 6:11 PM
Study NCT ID:
NCT03631732
Status:
COMPLETED
Last Update Posted:
2021-09-05
First Post:
2018-08-13
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants
Sponsor:
Gilead Sciences
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-08-28
Start Date Type:
ACTUAL
Primary Completion Date:
2019-08-12
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-08-19
Completion Date Type:
ACTUAL
First Submit Date:
2018-08-13
First Submit QC Date:
None
Study First Post Date:
2018-08-15
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2020-08-12
Results First Submit QC Date:
None
Results First Post Date:
2020-08-27
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-08-09
Last Update Post Date:
2021-09-05
Last Update Post Date Type:
ACTUAL